1. Home
  2. GO vs CRVS Comparison

GO vs CRVS Comparison

Compare GO & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grocery Outlet Holding Corp.

GO

Grocery Outlet Holding Corp.

HOLD

Current Price

$11.04

Market Cap

1.1B

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

N/A

Current Price

$14.85

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GO
CRVS
Founded
1946
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
GO
CRVS
Price
$11.04
$14.85
Analyst Decision
Hold
Strong Buy
Analyst Count
10
6
Target Price
$11.30
$30.17
AVG Volume (30 Days)
2.8M
784.6K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.04
EPS
N/A
N/A
Revenue
$4,688,759,000.00
N/A
Revenue This Year
$2.48
N/A
Revenue Next Year
$3.91
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.26
N/A
52 Week Low
$5.66
$5.03
52 Week High
$19.23
$26.95

Technical Indicators

Market Signals
Indicator
GO
CRVS
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
GO
CRVS

About GO Grocery Outlet Holding Corp.

Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: